Bita blockers
Reading File
Finding Sources
Searching PubMed
beta-blockers clinical use cardiovascular
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Here is a thorough overview of beta-blockers, synthesized from authoritative textbook sources:
Beta-Blockers (Beta-Adrenergic Antagonists)
Mechanism of Action
Beta-blockers competitively antagonize catecholamines (norepinephrine, epinephrine) at beta-adrenergic receptors. Their key effects are:
- Decreased heart rate (negative chronotropy) - by slowing SA node firing
- Decreased contractility (negative inotropy) - by reducing adrenergic drive
- Decreased AV conduction - PR interval may be prolonged
- Reduced blood pressure - through combined cardiac and vascular effects
- Reduced myocardial oxygen demand - by decreasing workload
Most harmful effects of sympathetic activation are mediated through the beta-1 (beta-1) receptor, which is the primary target. - Roberts and Hedges' Clinical Procedures in Emergency Medicine
Classification by Receptor Selectivity
| Category | Drugs | Notes |
|---|---|---|
| Non-selective (beta-1 + beta-2) | Propranolol, Nadolol, Timolol, Sotalol, Carteolol, Pindolol | Block both beta-1 and beta-2 receptors |
| Beta-1 selective ("cardioselective") | Metoprolol, Atenolol, Bisoprolol, Betaxolol, Nebivolol, Acebutolol | Preferred in COPD/asthma (less bronchospasm risk); selectivity is LOST at high doses |
| Alpha + Beta blockers | Carvedilol, Labetalol | Block alpha-1 as well; useful in HF and hypertensive urgency |
| With ISA (intrinsic sympathomimetic activity) | Pindolol, Acebutolol, Penbutolol | Partial agonists; cause less bradycardia at rest |
Note: Selectivity is lost in overdose - all beta-blockers inhibit both beta-1 and beta-2 at high doses. - Katzung's Basic and Clinical Pharmacology, 16th Ed.
Indications
| Condition | Agents Proven Effective | Key Notes |
|---|---|---|
| Hypertension | Most beta-blockers | Often combined with other agents |
| Chronic Heart Failure (HFrEF, EF <40%) | Bisoprolol, Carvedilol, Metoprolol succinate | Only these 3 have mortality benefit; start low, titrate slowly over 2-week intervals |
| Post-MI | All (especially propranolol, metoprolol, carvedilol) | Reduce mortality; see update below |
| Stable Angina | Propranolol, metoprolol, atenolol | Reduce O2 demand |
| Arrhythmias | Metoprolol, atenolol, propranolol, esmolol, sotalol | Useful in SVT, AF rate control, atrial flutter, MAT |
| Thyrotoxicosis | Propranolol | Controls adrenergic symptoms |
| Migraine prophylaxis | Propranolol, metoprolol | |
| Essential tremor | Propranolol | |
| Pheochromocytoma | Used AFTER alpha-blockade | Never start beta-blocker first - can worsen HTN |
| Glaucoma | Timolol, betaxolol (ophthalmic) | Reduce aqueous humor production |
In heart failure, beta-blockers are biphasic in effect: early short-term deterioration (loss of adrenergic support) followed by long-term improvement, including reverse LV remodeling, improved LVEF, reduced hospitalizations and mortality. - Braunwald's Heart Disease
Contraindications
- Asthma / significant reactive airway disease - beta-2 blockade causes bronchospasm (use with extreme caution; cardioselective agents may be tolerated)
- Bradycardia or heart block (2nd or 3rd degree AV block without pacemaker)
- Hypotension
- Decompensated/acute heart failure - can worsen acutely
- Vasospastic (Prinzmetal) angina - may worsen coronary vasospasm
- Concurrent calcium channel blocker use (additive bradycardia/hypotension risk)
- AF with pre-excitation (WPW) - can accelerate conduction via bypass tract
- Diabetes (relative) - can mask signs of hypoglycemia (esp. tachycardia)
- Peripheral vascular disease (relative) - may worsen limb ischemia
Key Adverse Effects
| Effect | Mechanism |
|---|---|
| Bradycardia / heart block | Beta-1 blockade at SA/AV node |
| Fatigue, exercise intolerance | Reduced cardiac output |
| Bronchospasm | Beta-2 blockade in airways |
| Cold extremities | Beta-2 blockade in peripheral vasculature |
| Masking of hypoglycemia | Beta-2 blockade inhibits glycogenolysis/gluconeogenesis and tachycardia response |
| CNS effects | Lipophilic agents (propranolol) cross BBB - nightmares, depression, insomnia |
| Worsening fluid retention | Especially on initiation in HF |
Overdose / Toxicity
-
Propranolol is the most toxic beta-blocker: lipophilic (CNS penetration), plus sodium-channel blocking activity (similar to tricyclic antidepressants - wide QRS, seizures)
-
Most toxic effects: bradycardia and hypotension
-
Agents with ISA (e.g., pindolol) can paradoxically cause tachycardia and hypertension in overdose
-
IV fluids, atropine, and beta-agonists are generally ineffective in overdose
-
Antidote: Glucagon (5-10 mg IV) - raises intracellular cAMP independently of beta receptors, improving HR and BP
-
Katzung's Basic and Clinical Pharmacology, 16th Ed.
Selected Commonly Used Agents
| Drug | Selectivity | Route | Notes |
|---|---|---|---|
| Propranolol | Non-selective | PO, IV | Prototype; most lipophilic; many uses |
| Metoprolol (tartrate/succinate) | beta-1 selective | PO, IV | Succinate is extended-release; proven in HF |
| Atenolol | beta-1 selective | PO | Renally cleared; less CNS penetration |
| Bisoprolol | beta-1 selective | PO | Proven mortality benefit in HF |
| Carvedilol | alpha-1 + beta-1 + beta-2 | PO | Proven in HF; vasodilation |
| Labetalol | alpha-1 + beta (non-selective) | PO, IV | IV use in hypertensive urgency, preeclampsia |
| Esmolol | beta-1 selective | IV only | Ultra-short acting (half-life ~9 min); useful in acute settings |
| Sotalol | Non-selective | PO | Also a Class III antiarrhythmic |
| Nebivolol | beta-1 selective | PO | Also releases NO (vasodilatory) |
| Timolol | Non-selective | Ophthalmic | Glaucoma |
Recent Evidence Updates (2025-2026)
Important update on post-MI use: A 2026 meta-analysis in the New England Journal of Medicine (PMID: 41211954) examined beta-blockers after MI with normal ejection fraction. This is an evolving area - the traditional blanket recommendation to give beta-blockers long-term post-MI may not apply to patients with preserved EF. Clinicians should watch for updated guidelines.
A 2025 Lancet systematic review (PMID: 40885583) on antihypertensive efficacy found that beta-blockers remain effective for blood pressure lowering, particularly in combination.
A 2025 JACC network meta-analysis (PMID: 40892608) confirmed that beta-blockers (bisoprolol, carvedilol, metoprolol succinate) remain cornerstone therapy in HFrEF.
Sources: Braunwald's Heart Disease | Katzung's Basic and Clinical Pharmacology, 16th Ed. | Roberts and Hedges' Clinical Procedures in Emergency Medicine | Tintinalli's Emergency Medicine
This is a shared conversation. Sign in to Orris to start your own chat.